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ABSTRACT
Objectives: If leprosy is a public health problem, it is
due to the disabilities it causes. Surprisingly little is
known about the risk of disabilities. Even now, mainly
cross-sectional studies report disability prevalence.
The present study aims to report the risk of disability in
pre and post-WHO multidrug therapy (MDT) in
multibacillary leprosy patients and to assess the extent
of the incidence of disability.
Methods: The study design is prospective and the
setting is an institutional ﬁeld area. Patients were
detected during 2001e6 ﬁeld surveys. Of the 289
multibacillary patients, 146 completed the study. Both
sexes were involved. The primary outcome planned
was to study cure of disease, relapses and disability in
patients receiving MDT. The secondary outcome was
to measure reaction and default. Assessment was
done clinically. Data have been analysed using SPSS
software, logistic, survival analysis was performed and
the c
2 test of signiﬁcance was used.
Results: An important risk factor was found to be
three or more nerves involved with odds of 3.73
(1.24e11.2), and delay in treatment; 2.27 (1.04e4.96)
at the pre-MDT stage and three or more nerves
involved with odds of 2.81 (1.0e7.9) at the post-MDT
stage. The incidence of disability was found to be 2.74/
100 person-years; 2.69 in the MDT arm and 2.84 in
defaulters, with slightly higher disability among early
defaulters (3.08) than among late defaulters (2.30).
The study suggests that the incidence of disability
could be slightly higher if treatment is not completed.
Conclusion: Early treatment for leprosy is a must for
reducing the risk of disability, and treatment delay
would increase the risk of disability. It is important to
note that the incidence of disability between defaulters
and those completing treatment was not found to be
signiﬁcantly different.
If leprosy is a public health problem, it is due
to the disabilities it causes. It was surprising
to note that this being so important, very
little was known about the risk of disabilities
1
and even now there are mainly cross-sectional
studies at the population level that reports
disability prevalence among leprosy patients.
The prevalence of disability, however, varies
signiﬁcantly from one study to another. In
the Malawi study, disability prevalence varied
from 20% to 10% during 1973e87.
1 The
studies performed in India
2 6 reported
a visible deformity rate from 2.8% to 24.3%
among cases at registration or detection in
population surveys. However, very few studies
on the risk of developing disabilities have
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ARTICLE SUMMARY
Article focus
- What are the risk factors associated with
disability at the pre-MDT and post-MDT stage?
- What is the risk of disability among leprosy
patients, patients completing treatment versus
defaulters?
- Do early defaulters have a higher incidence of
disability than late defaulters?
Key messages
- This study clearly demonstrates that risk factors
for disability at detection and in a prospective
cohort are the same, ie, an increasing number of
nerves thickening. It also reveals that the
incidence of disability although high among
defaulters (2.84/100 person-years) is not signif-
icantly higher than in those completing treatment
(2.42/100 person-years); nor does it differ
signiﬁcantly among early versus late defaulters
(3.08 vs 2.30). In addition, it shows that
treatment with ROM has much better prevention
than in MDT groups. All this together implies that
even a few months of treatment could be as good
as completing treatment as far as the develop-
ment of disability is concerned, but treatment
must be started.
Strength and limitations of this study
- The strength of the study is that it is based on
a closely followed prospective cohort for a good
length of time and patients were clinically
assessed and monitored. However, one limitation
could be that the ROM arm could not be
completed due to WHO withdrawal. This could
have provided more comparable data.
Kumar A, Girdhar A, Girdhar BK. BMJ Open 2012;2:e000361. doi:10.1136/bmjopen-2011-000361 1
Open Access Researchbeen undertaken. Although the Malawi study
1 had
reported the risk of developing disabilities as 5/1000
person-years during the pre-multidrug therapy (MDT)
era, and the south India study
2 observed a disability
rate of 6.8%, this was a crude estimate without referring
to time. The risk of developing disabilities is also
very important for the national programme on the
prevention of disabilities.
This study was therefore attempted to assess the risk/
incidence of developing disability among those leprosy
patients who had no disability at the time of detection
in ﬁeld surveys but developed it during the years of
follow-up after completion of WHO MDT.
DESIGN AND METHODS
Study site, ﬁeld setting and duration of study
The study was started in our ﬁeld area in the Agra district
of Uttar Pradesh on patients detected in ﬁeld surveys
under several studies on the prevalence of leprosy
during 2001e6.
3e6 The Agra district is located 200 km
away from Delhi and spreads in the radius of 100 km on
either side in length and borders with the districts of
Itawa and Firozabad on the eastern side, Mathura and
Bharatpur on the north-west side and Gwalior and
Dholpur on the south side. Several studies have been
undertaken because the district was highly endemic for
leprosy, with a prevalence of 16.4/10000 during 2001e3
and 7/10000 during 2004e6. The present study is based
on patients detected in such surveys and all patients were
followed up to April 2011.
Inclusion/exclusion criteria of patients for the study
Newly detected leprosy patients diagnosed clinically as
multibacillary leprosy were included in the study. This
included patients with more than ﬁve skin lesions, either
erythmatous or hypopigmented with deﬁnite impair-
ment or loss of sensation (tested with a ballpoint pen) or
more than two thickened nerves. None of the patients
had taken leprosy treatment earlier. Children younger
than 5 years and adults above 70 years were treated as
per the norm but were not included in the study and so
were pregnant and lactating women.
Cohort size and treatment allocation and assessment on
follow-up
Two hundred and ninety-three leprosy cases with multi-
bacillary leprosy were detected. Of these 293, four
patients did not start the treatment. The study was
initially aimed to study the difference in the outcome of
the two treatment arms (100 patients in each arm), ie,
rifampicin 600 mg, oﬂoxacin 400 mg and minocycline
200 mg (ROM) for adults and half of it for children
(<15 years) as recommended by WHO versus WHO
standard MDT (rifampicin, oﬂoxacin and dapsone)
given monthly for 12 months. As WHO suddenly with-
drew the ROM supply in 2003, only a small number of
patients (22) were randomly allocated (using a random
numbers table) to the ROM arm by then and later on all
the cases detected were put on MDT. Therefore, this
study now aimed at studying the risk of relapse and
disability among MDT-treated cases and the ROM arm
was not included in the study. An attempt was also made
to compare the risk of disability among those completing
treatment compared with those who defaulted; either
early (within 6 months) or late (during 6e11 months).
All the cases that were started on treatment were followed
up monthly to treatment completion, 6-monthly up to
3 years and then annually to the end of the study.
Disability grade 1 was deﬁned as the patient developing
anaesthesia in the palm or sole tested with a ballpoint
pen and grade 2 as visible deformity in either the hands,
feet or eyes (lagophthalmas). During this time, all cases
of clinical relapse, reaction and development of disability
Table 1 Prevalence of grade 2 disability at detection in
multibacillary leprosy patients by demographic and clinical
status, Agra district (Uttar Pradesh) India during 2001e6
Characteristics
MDT arm (267)
Cases
% Grade 2
disability
Age, years
#14 17 5.9
15e24 25 4.0
25e34 40 5.0
35e54 108 13.9
>54 77 10.4
Total 267 10.1
Mean (SEM) 43.4 (1.1)
Sex
Male 163 14.1
Female 104 3.9
Delay in detection, months
#12 67 6.0
13e36 103 8.7
>36 97 14.4
Patches
0 12 50.0
1e5 16 25.0
6e10 84 3.6
>10 155 9.0
Nerves
0e2 99 4.0
3e5 101 11.9
>5 67 16.4
Clinical status
BT/BTR 131 3.8
BB/BBR 74 5.4
BL/LL 51 25.5
N 11 45.5
Treatment status
Defaulters 92 8.7
Completed 175 10.9
Smear
Positive 27 7.4
Negative 138 6.5
Not done 102 15.7
BB, borderline borderline; BL, borderline lepromatous; BT,
borderline tuberculoid; LL, lepromatous; MDT, multidrug therapy;
R, reaction at diagnosis.
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Risk of disabilities in multibacillary leprosy(grade 1 and grade 2) were recorded after medical
conﬁrmation and necessary medical relief was either
provided or they were referred (see ﬂow chart).
Deﬁning some parameters
A leprosy patient detected with leprosy-related disability
at the time of detection in the ﬁeld survey was deﬁned as
prevalence of disability. The occurrence of disability
detected at follow-up in previously detected leprosy
cases without disability at that time was deﬁned as inci-
dence of disability. Delay at detection or treatment is the
same, ie, duration of untreated disease as reported at
ﬁrst detection.
Ethics approval and informed consent
Ethics approval was granted by the institutional ethical
committee, which was being informed periodically about
the progress of the work. All the patients were informed
about the possible side effects, remedies and beneﬁts.
Although the treatment given was a WHO standard
regimen, for reasons of follow-up etc the patients were
asked to consent and then they were put on respective
treatment. In case of children, consent of their parents
was obtained.
Table 2 CID by demographic and clinical status at follow-up among multibacillary leprosy patients by treatment compliance
status, Agra district (Uttar Pradesh) India
Charaecterstics
Completed treatment Defaulters c
2 with p value
Cases CID rate Cases CID rate Completed treatment Defaulters
Age, years
#14 12 0 2 0 >0.05 >0.05
15e24 15 6.7 3 33.3
25e34 30 9.7 9 0
35e54 64 15.6 25 12.0
>54 41 7.3 20 20.0
Total 162 10.5 59 13.6
Sex
Male 101 12.9 28 14.3 >0.05 >0.05
Female 61 6.6 31 12.9
Delay in treatment, months
#12 44 6.8 14 7.1 >0.05 >0.05
13e36 63 11.1 26 11.5
>36 55 12.7 19 21.1
Patches
0 5 60.0 0 0 15.0, 0.002 >0.05
1e56 0 4 0
6e10 62 6.5 13 0
>10 90 11.1 42 19.0
Nerves
0e2 66 4.8 28 7.1 >0.05 7.7, 0.021
3e5 60 11.7 17 5.9
>5 39 17.9 14 35.7
Clinical status
BT/BTR 94 4.3 24 8.3 19.6, <0.001 >0.05
BB/BBR 38 13.2 23 21.7
BL/LL 25 20.0 12 8.3
N 5 60.0 0 0
Smear
Positive 101 8.9 28 17.9 >0.05 >0.05
Negative 19 10.5 4 0
Not done 42 14.3 27 11.1
BB, borderline borderline; BL, borderline lepromatous; BT, borderline tuberculoid; CID, crude incidence of disability; LL, lepromatous;
R, reaction at diagnosis.
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Risk of disabilities in multibacillary leprosyStatistical methods
The comparison of patients developing disability was
performed using survival analysis and the log rank test to
test the signiﬁcance using SPSS V.12 software and
Fisher’s exact test or the c
2 test of signiﬁcance used to
compare proportions.
7 The logistic regression analysis
was done to undertake risk factor analysis.
RESULTS
Demographic characteristics of patients
Patients of all ages were detected in surveys. The mean age
was 43.4 years (SEM 1.1) with a median of 45 years. Most
patients (69.3%) were aged 35 years and above and only
6.4% were children. Male patients in this study accounted
for 61.0% of the total 267 cases started on multibacillary
MDT. At the time of survey, 25.1% of patients were those
who reported acquiring leprosy during the past
12 months, 38.6% in the past 12e36 months and the rest
had had the disease for over 36 months.
Prevalence of disability at detection
The prevalence of grade 2 disability (visible) was found to
be 10.1%. The prevalence of grade 2 disability seems to
increasee slowly with increased age, and male patients had
greater disability (14.1 vs 3.8, c
2¼7.4, p¼0.007) than the
female patients. The prevalence of disability also
increased among patients who delayed treatment for
a longer period particularly beyond 36 months (c
2¼6.2,
p¼0.032). Signiﬁcantly greater disability was noted
among patients with three or more thickened nerves
(c
2¼7.3, p¼0.026), and among patients with an advanced
clinical stage of disease (BL (borderline lepromatous)/
LL (lepromatous) or neuritic) (c
2¼37.9, p¼0.000) than
among those with early stage disease (BT (borderline
tuberculoid)/BB (borderline borderline)). However, the
prevalence of disability did not vary signiﬁcantly among
patients who defaulted from treatment compared with
those who completed treatment (c
2¼0.45, p¼0.80) and
by smear status (c
2¼4.6, p¼0.10) see table 1.
Crude incidence of disability
The crude incidence of disability (CID) is presented in
table 2. The CID was observed to be 13.6% among treat-
ment defaulters, greater than 10.5% among those who
completed treatment, but was not signiﬁcantly different
(p>0.05) nor did it increase signiﬁcantly by the age of the
patients (p>0.05). Although men had a higher incidence
of disability than women (14.3 vs 12.9 in defaulters and
12.9 vs 6.6 in the completing treatment group), the
difference was not signiﬁcant (p>0.05). The CID was
found to be signiﬁcantly higher among MDT patients
with neuritic leprosy (patch 0) or in those with more than
10 patches (c
2¼15.0, p¼0.002). The patients with three
or more thickened nerves who still defaulted had signiﬁ-
cantly greater disability (c
2¼7.7, p¼0.021) in comparison
with those patients on MDT who completed their
Table 3 Risk factors for prevalence of disability at detection (pre-MDT stage)
OR (95% CI) OR (95% CI) OR (95% CI)
Nerves
0e2 1.0 1.0 1.0
3 or more 4.53 (1.54 to 13.4) 3.87 (1.30 to 11.6) 3.73 (1.24 to 11.2)
Age, years
<35 e 1.0 1.0
$35 e 2.49 (0.83 to 7.50) 2.35 (0.77 to 7.12)
Delay in treatment, months
#36 ee1.0
>36 ee2.27 (1.04 to 4.96)
Standardised for None Age Age and delay in treatment
MDT, multidrug therapy.
Table 4 Risk factors for incidence of disability post-MDT
OR (95% CI) OR (95% CI) OR (95% CI)
Nerves
0e2 1.0 1.0 1.0
3 or more 3.05 (1.10 to 8.48) 2.84 (1.01 to 8.0) 2.81 (1.0 to 7.90)
Age, years
<35 e 1.0 1.0
$35 e 1.63 (0.57 to 4.58) 1.64 (0.58 to 4.68)
Delay in treatment, months
#36 ee1.0
>36 ee1.22 (0.57 to 2.61)
Standardised for None Age Age and delay in treatment
MDT, multidrug therapy.
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Risk of disabilities in multibacillary leprosytreatment. Patients in the MDT arm who had disease of
a high clinical spectrum such as BL/LL/neuritic leprosy
were observed to have a signiﬁcantly greater incidence of
disability (c
2¼19.6, p<0.001). However, no difference was
found by the smear positivity status of patients.
Risk factors for prevalence of disability (pre-MDT stage)
Using logistic regression analysis, an attempt was made
to assess the role of risk factors known to be responsible
for causing disability. It was found that patients with the
involvement of three or more nerves had a 4.53 times
higher risk of disability (OR 4.53, 95% CI 1.54 to 13.4)
presenting at detection, and after adjusting the effect of
age and delay in treatment, this showed (OR 3.73, 95%
CI 1.24 to 11.2) than in others. The second highest risk
was found for the factor ‘delay at detection’ for treat-
ment beyond 36 months, ie, OR 2.27, 95% CI 1.04 to
4.96, compared with those who started treatment within
36 months of having disease-adjusted for age (table 3).
Risk factors for incidence of disability (post-MDT stage)
The risk of the incidence of disability was assessed
among those who were free from disability at the time of
detection. It was found that the incidence of disability
was high (OR 3.05, 95% CI 1.10 to 8.48) among patients
with three or more nerves involved and remained so
(OR 2.81, 95% CI 1.0 to 7.9) when standardised for age
and delay in treatment (table 4).
Incidence of disability
A detailed analysis of the incidence of disability has been
presented using survival analysis among different
groups. The overall incidence of disability was found to
be 2.74/100 person-years with a mean follow-up of
4.28 years after treatment completion or from the point
of default (table 5). The incidence of disability was
2.69/100 person-years during a mean follow-up of
4.08 years in those patients completing MDT and
2.84/100 person-years during a mean of 4.78 years after
default (see ﬁgures 1 and 2).
The comparison of the incidence (hazard) curve by
years of follow-up did not suggest a signiﬁcant difference
between the two treatment groups (log rank test 0.02,
p¼0.88).
Table 5 Incidence of disability/1000 person-years of follow-up
Treatment group Cases
Mean years
survival time Person-years
Disability
developed in
Incidence/100
person-years
Completed treatment MDT 146 4.08 594.7 16 2.69
Defaulters of MDT 59 4.78 281.9 08 2.84
Early (<6 months of
treatment)
38 5.12 194.9 06 3.08
Late (6e11 months of
treatment)
21 4.14 87.0 02 2.30
All 205 4.28 876.6 24 2.74
MDT, multidrug therapy.
Figure 1 Incidence of disability in multibacillary leprosy
patients who completed treatment.
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Figure 2 Risk of developing disability among multibacillary
leprosy patients post-multidrug therapy by treatment
compliance.
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Risk of disabilities in multibacillary leprosyA further analysis between early defaulters and late
defaulters, although showing that early defaulters had
the greatest incidence of disability (3.08/100 person-
years) compared with 2.3/100 person-years in the group
of late defaulters, but the incidence curve over the years
of follow-up did not differentiate between the two
statistically (p>0.05) (see ﬁgures 3 and 4).
DISCUSSION
This study provides a unique opportunity to assess the
role of factors associated with the prevalence of disability
at a case detection stage in active surveys and also the
incidence of disability when patients of varying treat-
ment status are followed up for years. The risk factors for
the development of disability among multibacillary
patients appeared to be almost similar with increased
nerve thickening (three or more nerves) as the number
one risk factor, and delay in treatment beyond
36 months was the number 2 risk factor. A study
conducted to assess the risk of paralytic deformity (grade
2 and above) among cases detected in surveys had shown
that patients with skin lesions who also had three to ﬁve
nerves involved were found to have a very high risk (OR
33.4) of deformity.
8 However, the patients with neuritic
leprosy (no skin lesions) with delay in diagnosis for
treatment of beyond 5 years had 17.5 times (OR) the risk
of developing deformity than among those with a lesser
delay.
8
The incidence of disability among these patients was
found to be 2.74/100 person-years of follow-up; 2.69 in
the MDT arm and 2.84 in treatment defaulters, with
33.9% (3.08 vs 2.30) greater disability among early
defaulters (3.08) and 2.30 among late defaulters. The
study therefore clearly suggests that the incidence of
disability could be only slightly higher 6% (2.84 vs 2.69)
in the group completing the required MDT than in those
defaulting. The risk of disability in the present study was
found to be higher than in the Malawi study (5/1000
person years).
1 The CID in this study was also higher
(10.5%) among those completing MDT treatment than
6.8% in the south India study
2 conducted during
1985e92. However, the reasons for the higher incidence
of disability in this study are not clearly known. One of
the possible reasons could be that pathways for disabil-
ities are set in before the treatment started, and thus the
occurrence of disability could not be altered. Second,
once the disease affects an individual, the treatment may
not be able to prevent disability. However, in the absence
of proper studies, these are just possibilities.
CONCLUSION
The important conclusion of the study is that the initi-
ation of treatment for leprosy is a must for reducing the
risk of the incidence of disability, and delays in initiating
treatment would increase the risk of disability by many
fold. It is important to note that the incidence of
disability between defaulters and those completing
treatment was not found to be signiﬁcantly different.
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